T 1732/18 of 27.10.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T173218.20211027
- Date of decision
- 27 October 2021
- Case number
- T 1732/18
- Online on
- 16 May 2022
- Petition for review of
- -
- Application number
- 06706291.9
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- TREATMENT OF THROMBOEMBOLIC DISORDERS WITH RIVAROXABAN
- Applicant name
- Bayer Intellectual Property GmbH
- Opponent name
- Breuer, Markus (opposition withdrawn)
Actavis Group PTC ehf
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Teva Pharmaceutical Industries Ltd.
STADA Arzneimittel AG
Generics [UK] Limited (trading as Mylan)
Abdi Ibrahim Ilaç Sanayi ve Ticaret Anonim Sirketi
Wittkopp, Alexander
Galenicum Health S.L.
ABG Intellectual Property Law, S.L.
Stolmár, Matthias
Hexal AG
Kraus & Weisert Patentanwälte PartGmbB
Zentiva k.s.
Krka, d.d., Novo mesto - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 105European Patent Convention R 79European Patent Convention Art 113(1)Rules of procedure of the Boards of Appeal 2020 Art 013(2)European Patent Convention Art 100(b)European Patent Convention Art 56
- Keywords
- Amendments - added subject-matter (no)
Novelty - (yes)
Admittance of evidence filed in Appeal
Admittance of submissions filed at a late stage
Sufficiency of disclosure (yes)
Inventive step - (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The oppositions are rejected.
3. The patent is maintained as granted.